Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: A retrospective study

Rossella De Luca, Carlo Pavone, Alchiede Simonato, Francesco Dieli, Giuseppe Cicero, Alessio Pepe, Rossella De Luca, Giuseppe Cicero, Alessio Pepe, Livio Blasi, Alchiede Simonato, Carlo Pavone

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% confidence interval:-0.30 to 0.80) (P=0.005). Meanwhile, regression analysis revealed that PSA levels are predictive of OS. There was a positive correlation with OS, which showed a value of R 2 to 0.50 with a slope of 1.44 (P=0.0021). Abiraterone is a well-Tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer. The drug has a better tolerability profile, gives significant pain relief, and increases the survival rate.
Original languageEnglish
Pages (from-to)1047-1052
Number of pages6
JournalAnti-Cancer Drugs
Volume28
Publication statusPublished - 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: A retrospective study'. Together they form a unique fingerprint.

Cite this